Navigation Links
Scientists Receive Patent for Development of "combination" Proteins to Produce Vaccines for Lyme Disease

UPTON -- Scientists belonging to the U.S. Department of Energy's Brookhaven National Laboratory and collaborators at Stony Brook University have been granted// the U.S. Patent Number 7,179,448 which will allow them to develop chimeric, or "combination," proteins that will accelerate the development of vaccines and diagnostic tests for Lyme disease.

The genetically engineered proteins combine pieces of two proteins that are normally present on the surface of the bacterium that causes Lyme disease, but at different parts of the organism’s life cycle. "Combining pieces of these two proteins into one chimeric protein should trigger a 'one-two-punch' immune response more capable of fending off the bacterium than either protein alone," says Brookhaven biologist John Dunn, a researcher on the BNL Lyme disease team. "These chimeric proteins could also be used as diagnostic reagents that distinguish disease-causing strains of bacteria from relatively harmless ones, and help assess the severity of an infection," Dunn said.

Lyme disease is the most common vector-borne disease in the U.S., causing approximately 25,000 new cases each year — a rate that is expected to increase by at least a third from 2002 to 2012, according to a new study. Early symptoms of the disease, which is spread by the bite of an infected deer tick, include a bull's-eye rash at the site of the bite and flu-like symptoms. If not promptly treated with antibiotics, it can lead to more serious symptoms, including joint and neurological complications.

Scientists have been working on vaccines based on the structures of proteins found on the outer surface of Borrelia burgdoferi, the bacterium that causes Lyme disease. Dunn and colleagues deciphered the atomic level structures of these proteins, known as outer surface proteins A and C (OspA and OspC), at the National Synchrotron Light Source (NSLS) at Brookhaven Lab. The OspA protein, which was used to make the original vaccine again st Lyme disease, is only present in the bacteria while they are in the cold-blooded deer tick’s stomach, and not in the host. After the tick bites a warm-blooded mammalian host, the injected bacteria produce OspC on their surface.

With the aim of developing a vaccine that would trigger an immune response against both these life cycle stages, Dunn's team used methods of recombinant DNA to create new proteins that combine the most immunogenic portions of OspA and OspC — that is, the regions of the two proteins that are most likely to trigger an immune response.

The researchers have demonstrated that the new combination proteins retain the ability to trigger an immune response to at least one or both of the antigens, and can trigger the production of antibodies that inhibit growth of and/or kill Borrelia bacteria in laboratory cultures. They've also shown that the chimeric proteins can be mass-produced in E. coli bacteria, a common laboratory technique for making proteins, and easily purified for possible use in vaccines or diagnostic assays.

"This could lead to a vaccine that is effective at different stages of the organism’s life cycle," said Dunn. Moreover, by incorporating unique protein fragments from various pathogenic families of Borrelia, these chimeric proteins could be used to distinguish clinically important exposure to disease-causing Borrelia from exposures to other non-pathogenic families of Borrelia.

The patent covers the development of the chimeric proteins themselves, the nucleic acids (genetic material) used to generate the proteins, the methods used to make the proteins, the methods used to deliver either the proteins or nucleic acids, the use of the proteins in diagnostic assays or kits, and their use in animals and humans as vaccines against Lyme disease.

This research was funded by the Office of Biological and Environmental Research within the U.S. Department of Energy’s Office of Science a nd by the National Institutes of Health.

Source-Eurekalert
AV/B
'"/>




Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. Scientists found ancient Human Germ Killer
3. Scientists locate key hormone involved in appetite control
4. Scientists open the book of life
5. Scientists review SARS
6. Scientists crack dengue fever puzzle
7. Scientists push to lower hidden sodium in food
8. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
9. Scientists have found effective brain regions for deep brain stimulation for Parkinson’s
10. Scientists reveal the secrets of sarcasm
11. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... ... March 23, 2017 , ... 82% of adults are unaware of the dangers that ... brush their teeth the minimum two times a day that dentists recommend. The ramifications of ... million hours of school and adults missing 164 million hours of work each year due ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Accreditation from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive ... is granted to organizations that have excellent programs for the delivery and improvement ...
(Date:3/23/2017)... ... 23, 2017 , ... Michael Lanteri Agency, an insurance and ... area, has unveiled a collaboration with nonprofit Big Bones Canine Rescue as the ... cause may now be made at http://bigbonescaninerescue.com/ . , Big Bones Canine ...
(Date:3/23/2017)... ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and Health System ... AMN Healthcare: Susan Salka , 43rd President of the United States of America: ... My Life In and Out of the Ring: Sugar Ray Leonard , JD, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, a company known ... health and nutrition, announced its product Leyzene is now available for purchase on ... supplements that help people improve all aspects of their health so they can ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... SAO PAULO , March 23, 2017 ... accordance with article 157, paragraph 4 of Law 6,404/76 ... Commission (CVM), hereby informs its shareholders and the market ... jointly with its subsidiary Centro de Diagnosticos por Imagem ... acquisition of 100% interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" ...
(Date:3/23/2017)... , March 23, 2017 Ascendis Pharma ... innovative TransCon technology to address significant unmet medical needs ... host a conference call and webcast on Monday, April ... Endocrine Society in Orlando, Florida , ... pipeline candidates (TransCon Growth Hormone, TransCon PTH and TransCon ...
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD announces that AB Laboratories Inc. ... its licensed production facility under the Access to Cannabis ... Hamilton, Ontario . The facility, ... October 2016, is currently operating at half capacity, with ...
Breaking Medicine Technology: